{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:35:45Z","timestamp":1792445745988,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016714","name":"University of Sharjah","doi-asserted-by":"publisher","award":["24021440154"],"award-info":[{"award-number":["24021440154"]}],"id":[{"id":"10.13039\/100016714","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bioorg.2026.109859","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:18:16Z","timestamp":1776100696000},"page":"109859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design and synthesis of novel isatin-isoniazidhydrazone hybrid-based 1,2,3-triazoles as dual EGFR\/PARP-1 inhibitors and apoptosis inducers in breast cancer cells"],"prefix":"10.1016","volume":"176","author":[{"given":"Muna A.","family":"Alshams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Nafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Reda","family":"Aouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadjet","family":"Rezki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2024","key":"10.1016\/j.bioorg.2026.109859_bb0005","first-page":"229","article-title":"GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.109859_bb0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.109859_bb0015","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12935-024-03558-0","article-title":"Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy","volume":"24","author":"Mengistu","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bioorg.2026.109859_bb0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.109859_bb0025","series-title":"Small-Molecule Strategies to Combat Antibiotic Resistance: Mechanisms, Modifications, and Contemporary Approaches","author":"Elkady","year":"2025"},{"key":"10.1016\/j.bioorg.2026.109859_bb0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/10406638.2024.2392781","article-title":"Drugs and their mode of action: a review on Sulfur-containing heterocyclic compounds","volume":"45","author":"Kapoor","year":"2025","journal-title":"Polycycl. Aromat. Compd."},{"key":"10.1016\/j.bioorg.2026.109859_bb0035","doi-asserted-by":"crossref","first-page":"32188","DOI":"10.1039\/D5RA05002B","article-title":"A comprehensive review and recent advances on isatin-based compounds as a versatile framework for anticancer therapeutics (2020\u20132025)","volume":"15","author":"Alshams","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.109859_bb0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00044-013-0632-2","article-title":"Synthesis and evaluation of isonicotinoyl hydrazone derivatives as antimycobacterial and anticancer agents","volume":"23","author":"Naveen Kumar","year":"2014","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2026.109859_bb0045","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3390\/molecules26051272","article-title":"Synthesis of highly potent anti-inflammatory compounds (ROS inhibitors) from isonicotinic acid","volume":"26","author":"Yaqoob","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109859_bb0050","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s11030-024-10858-0","article-title":"An updated review on 1,2,3\u2212\/1,2,4-triazoles: synthesis and diverse range of biological potential","volume":"29","author":"Raman","year":"2025","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2026.109859_bb0055","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/0115734064278334231211054053","article-title":"Nitrogen-fused heterocycles: empowering anticancer drug discovery","volume":"20","author":"Biswas","year":"2024","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109859_bb0060","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1039\/C9MD00458K","article-title":"Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents","volume":"11","author":"Malik","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109859_bb0065","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.3390\/cancers16132478","article-title":"Emerging therapeutic strategies to overcome drug resistance in cancer cells","volume":"16","author":"Garg","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109859_bb0070","first-page":"451","article-title":"Molecular hybridization: a powerful tool for multitarget drug discovery, expert opin","volume":"19","author":"de Sena Murteira","year":"2024","journal-title":"Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109859_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1640365","article-title":"Unveiling the therapeutic potential of caudatin: structural optimization, pharmacological mechanisms, and therapeutic implications","volume":"16","author":"Shi","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109859_bb0080","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121979119","article-title":"Inhibitors of PARP: number crunching and structure gazing","volume":"119","author":"Rudolph","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2026.109859_bb0085","article-title":"Human PARP1 substrates and regulators of its catalytic activity: an updated overview","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109859_bb0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40265-015-0345-6","article-title":"Olaparib: first global approval","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109859_bb0095","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-017-0716-2","article-title":"Rucaparib: First global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109859_bb0100","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11523-018-0582-1","article-title":"Niraparib: a review in ovarian cancer","volume":"13","author":"Heo","year":"2018","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bioorg.2026.109859_bb0105","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","article-title":"Talazoparib: First global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109859_bb0110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.tibs.2009.12.003","article-title":"Toward a unified nomenclature for mammalian ADP-ribosyltransferases","volume":"35","author":"Hottiger","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bioorg.2026.109859_bb0115","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bcp.15015","article-title":"Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale","volume":"88","author":"Sandhu","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109859_bb0120","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1021\/acs.jctc.2c01171","article-title":"Strategy toward kinase-selective drug discovery","volume":"19","author":"Zhang","year":"2023","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.bioorg.2026.109859_bb0125","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/jm501603h","article-title":"Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors","volume":"58","author":"Vijayan","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109859_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.109859_bb0135","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.drudis.2017.05.014","article-title":"The 1,2,3-triazole ring as a bioisostere in medicinal chemistry","volume":"22","author":"Bonandi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2026.109859_bb0140","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1039\/b909064a","article-title":"Click polymerization","volume":"39","author":"Qin","year":"2010","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2026.109859_bb0145","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0968-0896(96)00058-2","article-title":"Parallel-compound synthesis: methodology for accelerating drug discovery","volume":"4","author":"Selway","year":"1996","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109859_bb0150","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.3762\/bjoc.17.130","article-title":"Correction: one-pot multicomponent green hantzsch synthesis of 1,2-dihydropyridine derivatives with antiproliferative activity","volume":"17","author":"Bosica","year":"2021","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.bioorg.2026.109859_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046614","article-title":"Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells","volume":"7","author":"Nowsheen","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.109859_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/genes13122183","article-title":"Mechanisms of EGFR-TKI-induced apoptosis and strategies targeting apoptosis in EGFR-mutated non-small cell lung cancer","volume":"13","author":"Nishihara","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.bioorg.2026.109859_bb0165","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1007\/s00018-010-0490-8","article-title":"Targeting poly(ADP-ribose) polymerase activity for cancer therapy","volume":"67","author":"M\u00e9gnin-Chanet","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bioorg.2026.109859_bb0170","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/cmdc.201600417","article-title":"Targeting a targeted drug: an approach toward hypoxia-Activatable tyrosine kinase inhibitor prodrugs","volume":"11","author":"Karnthaler-Benbakka","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.109859_bb0175","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11030-023-10603-z","article-title":"New antiproliferative 3-substituted oxindoles inhibiting EGFR\/VEGFR-2 and tubulin polymerization","volume":"28","author":"Ezelarab","year":"2024","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2026.109859_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202301612","article-title":"A comprehensive review of the diverse spectrum activity of 1,2,3-Triazole-linked isatin hybrids","volume":"21","author":"Rohila","year":"2024","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bioorg.2026.109859_bb0185","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00044-024-03230-2","article-title":"Recent pharmacological insights about imidazole hybrids: a comprehensive review","volume":"33","author":"Poyraz","year":"2024","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2026.109859_bb0190","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/00304948.2017.1320515","article-title":"Click synthesis and antimicrobial screening of novel Isatin-1,2,3-Triazoles with piperidine, morpholine, or piperazine moieties","volume":"49","author":"Aouad","year":"2017","journal-title":"Org. Prep. Proced. Int."},{"key":"10.1016\/j.bioorg.2026.109859_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2024.107471","article-title":"Isatin-1,2,3-triazole derivatives: synthesis, molecular docking and evaluation against acute experimental toxoplasmosis","volume":"260","author":"Arafa","year":"2024","journal-title":"Acta Trop."},{"key":"10.1016\/j.bioorg.2026.109859_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104133","article-title":"Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: synthesis, antitumor and mechanistic analyses","volume":"103","author":"Rezki","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109859_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2021.103125","article-title":"PARP1: structural insights and pharmacological targets for inhibition","volume":"103","author":"Spiegel","year":"2021","journal-title":"DNA Repair"},{"key":"10.1016\/j.bioorg.2026.109859_bb0210","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00044-023-03030-0","article-title":"Design, synthesis and anti-breast cancer properties of butyric ester tethered dihydroartemisinin-isatin hybrids","volume":"32","author":"Zhao","year":"2023","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2026.109859_bb0215","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1039\/D4RA07650H","article-title":"Design, synthesis, in vitro, and in silico studies of novel isatin-hybrid hydrazones as potential triple-negative breast cancer agents","volume":"15","author":"Munir","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.109859_bb0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2026.109859_bb0225","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2026.109859_bb0230","doi-asserted-by":"crossref","first-page":"17931","DOI":"10.1021\/acs.jmedchem.4c02052","article-title":"Dose\u2013Response Curves and the Determination of IC50 and EC50 Values","volume":"67","author":"Srinivasan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109859_bb0235","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1039\/D1NJ05655G","article-title":"The design and synthesis of potent benzimidazole derivatives via scaffold hybridization and evaluating their antiproliferative and proapoptotic activity against breast and lung cancer cell lines","volume":"46","author":"Elgawish","year":"2022","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2026.109859_bb0240","first-page":"83","article-title":"Evaluation of 2-Thioxoimadazolidin-4-one derivatives as potent anti-Cancer agents through apoptosis induction and antioxidant activation","volume":"27","author":"Nafie","year":"2021","journal-title":"In Vitro and In Vivo Approaches, Molecules"},{"key":"10.1016\/j.bioorg.2026.109859_bb0245","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cyto.990130802","article-title":"Features of apoptotic cells measured by flow cytometry","volume":"13","author":"Darzynkiewicz","year":"1992","journal-title":"Cytometry"},{"key":"10.1016\/j.bioorg.2026.109859_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.109087","article-title":"Triaryl dicationic DNA minor-groove binders with antioxidant activity display cytotoxicity and induce apoptosis in breast cancer","volume":"324","author":"Nafie","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2026.109859_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.carres.2019.107832","article-title":"Synthesis, molecular modeling and anti-cancer evaluation of a series of quinazoline derivatives","volume":"486","author":"Khodair","year":"2019","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.bioorg.2026.109859_bb0260","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/cbdd.13791","article-title":"Antimicrobial and antiproliferative activities of novel synthesized 6-(quinolin-2-ylthio) pyridine derivatives with molecular docking study as multi-targeted JAK2\/STAT3 inhibitors","volume":"97","author":"Nafie","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2026.109859_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2022.113323","article-title":"Evaluation of the binding performance of flavonoids to estrogen receptor alpha by autodock, autodock vina and Surflex-dock","volume":"233","author":"Xue","year":"2022","journal-title":"Ecotoxicol. Environ. Saf."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826003950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826003950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:48:44Z","timestamp":1778723324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826003950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":53,"alternative-id":["S0045206826003950"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109859","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of novel isatin-isoniazidhydrazone hybrid-based 1,2,3-triazoles as dual EGFR\/PARP-1 inhibitors and apoptosis inducers in breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109859"}}